Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Molecular basis of antifungal drug resistance in yeasts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic characterization confirms sporadic occurrence of vancomycin-resistant Enterococcus faecalis in Copenhagen, Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hyperbaric oxygen therapy augments tobramycin efficacy in experimental Staphylococcus aureus endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications, and usage

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. A clear conscience is the sure sign of a bad memory: Vancomycin-resistant enterococci and rectal thermometers

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Effects of Antibiotics on the Intestinal Microbiota of Mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pivmecillinam, a pro-drug of mecillinam, has been used extensively in Scandinavia for the treatment of acute lower urinary tract infections (UTIs) caused by Enterobacterales. It is still an attractive first-line drug for the empirical treatment of UTIs owing to the low prevalence of resistance as well as its favourable impact on the intestinal microbiota as a pro-drug and good in vitro efficacy against extended-spectrum β-lactamase (ESBL)- and plasmid-mediated AmpC β-lactamase-producing Escherichia coli. However, optimal dosing of pivmecillinam as well as its in vivo efficacy against UTIs caused by multidrug-resistant (MDR) broad-spectrum β-lactamase-producing E. coli has not been thoroughly studied. In this study, the efficacy of two mimicked human dosing regimens of pivmecillinam (200 mg and 400 mg three times daily) against clinical E. coli strains, including isolates producing ESBLs (CTX-M-14 and CTX-M-15), plasmid-mediated AmpCs (CMY-4 and CMY-6) and carbapenemases (NDM-1 and VIM-29), in a murine UTI model was compared. Both dosing regimens reduced the number of CFU/mL in urine for all strains, including mecillinam-resistant strains. Combining the effect for all six strains showed no significant differences in effect between doses for all three fluids/organs, but for each dose there was a highly significant effect in urine, kidney and bladder compared with vehicle-treated mice. Overall, this highlights the need for further studies to elucidate the role of mecillinam in the treatment of infections caused by MDR E. coli producing broad-spectrum β-lactamases, including specific carbapenemases.

TidsskriftInternational Journal of Antimicrobial Agents
Udgave nummer2
Sider (fra-til)105851
Antal sider6
StatusUdgivet - feb. 2020

Bibliografisk note

Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

ID: 58999798